DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $500 | +3.3% | 2,014 | 0.0% | 0.27% | +8.7% |
| Q2 2023 | $484 | -4.7% | 2,014 | 0.0% | 0.25% | -7.4% |
| Q1 2023 | $508 | -5.0% | 2,014 | 0.0% | 0.27% | -7.8% |
| Q4 2022 | $535 | -99.9% | 2,014 | 0.0% | 0.30% | -6.3% |
| Q3 2022 | $520,000 | +1.8% | 2,014 | 0.0% | 0.32% | +9.8% |
| Q2 2022 | $511,000 | -13.5% | 2,014 | 0.0% | 0.29% | +4.0% |
| Q1 2022 | $591,000 | -10.7% | 2,014 | 0.0% | 0.28% | -2.5% |
| Q4 2021 | $662,000 | +9.1% | 2,014 | +1.0% | 0.28% | +1.8% |
| Q3 2021 | $607,000 | +13.5% | 1,995 | 0.0% | 0.28% | +16.3% |
| Q2 2021 | $535,000 | +19.2% | 1,995 | 0.0% | 0.24% | +11.7% |
| Q1 2021 | $449,000 | +1.4% | 1,995 | 0.0% | 0.21% | -6.6% |
| Q4 2020 | $443,000 | +3.0% | 1,995 | 0.0% | 0.23% | -17.6% |
| Q3 2020 | $430,000 | +21.8% | 1,995 | 0.0% | 0.28% | +15.4% |
| Q2 2020 | $353,000 | +27.9% | 1,995 | 0.0% | 0.24% | +3.0% |
| Q1 2020 | $276,000 | -9.8% | 1,995 | 0.0% | 0.23% | +19.4% |
| Q4 2019 | $306,000 | +6.2% | 1,995 | 0.0% | 0.20% | -2.5% |
| Q3 2019 | $288,000 | +1.1% | 1,995 | 0.0% | 0.20% | +2.0% |
| Q2 2019 | $285,000 | +8.4% | 1,995 | 0.0% | 0.20% | +15.9% |
| Q1 2019 | $263,000 | +18.5% | 1,995 | -7.4% | 0.17% | +30.8% |
| Q4 2018 | $222,000 | -5.1% | 2,155 | 0.0% | 0.13% | +7.4% |
| Q3 2018 | $234,000 | +0.4% | 2,155 | -8.8% | 0.12% | -4.0% |
| Q2 2018 | $233,000 | +0.9% | 2,363 | 0.0% | 0.13% | 0.0% |
| Q1 2018 | $231,000 | +5.5% | 2,363 | 0.0% | 0.13% | +5.0% |
| Q4 2017 | $219,000 | +7.9% | 2,363 | 0.0% | 0.12% | +4.3% |
| Q3 2017 | $203,000 | +0.5% | 2,363 | 0.0% | 0.12% | -10.2% |
| Q1 2017 | $202,000 | -15.5% | 2,363 | 0.0% | 0.13% | -34.4% |
| Q2 2016 | $239,000 | +6.7% | 2,363 | 0.0% | 0.20% | +10.8% |
| Q1 2016 | $224,000 | +2.3% | 2,363 | 0.0% | 0.18% | -4.9% |
| Q4 2015 | $219,000 | +9.0% | 2,363 | 0.0% | 0.18% | +3.4% |
| Q3 2015 | $201,000 | -0.5% | 2,363 | 0.0% | 0.18% | +2.9% |
| Q2 2015 | $202,000 | +0.5% | 2,363 | 0.0% | 0.17% | +11.5% |
| Q1 2015 | $201,000 | -1.0% | 2,363 | 0.0% | 0.16% | -2.5% |
| Q4 2014 | $203,000 | – | 2,363 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |